Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

ATNM Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Actinium Pharmaceuticals, Inc.AMEX: ATNM

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue remains negative

Q2 FY2026 revenue was $35M, compared with $0 a year earlier. Trailing-twelve-month revenue was $35.09M. Over 3 fiscal years it compounded at -55.6% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 2 analysts of $35M (+38788.9%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$35M— QoQ
Last fiscal yearDec 2025
$90K— YoY
LTMJun 2026
$35.09M— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter—+1284.4%—
1 year—+38788.9%—
3-year CAGR-55.6%+176.4%+232.0 pp
5-year CAGR+140.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
90K USD
Year-over-year change
—
4-year CAGR
-47.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ATNM compares with its peers on the latest reported figures

  • ATNM's LTM Jun 2026 revenue of $35.09M is the 2nd highest of the 5 companies compared; the peer median is $0.
ATNM Competitors Peer median
Revenue for ATNM and competitors
Company Period LTM YoY 3-year CAGR
XLOXilio Therapeutics, Inc.LTM Mar 2026$53.48M +476.7%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$35.09M —-55.6%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$0 ——
PDSBPDS Biotechnology CorporationLTM Mar 2026$0 ——
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 ——
Peer median (excluding ATNM) $0+476.7%—

Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.14M1.03M81K090K
Cost of Revenue524K00811K0
Gross Profit620K1.03M81K(811K)90K
Gross Margin54.2%100.0%100.0%—100.0%
Research & Development17.51M23.14M38.67M30.05M21.12M
Selling, General & Admin8.08M12M13.33M12.08M15.21M
Operating Expenses25.58M35.13M52M41.31M36.34M
Depreciation & Amortization524K699K790K811K821K
EBITDA(24.25M)(32.32M)(48.03M)(37.43M)(33.07M)
EBITDA Margin-2119.8%-3137.7%-59293.8%—-36740.0%
Operating Income(24.96M)(34.1M)(51.92M)(42.12M)(36.25M)
Operating Margin-2182.2%-3311.1%-64098.8%—-40274.4%
Interest Income190K1.09M3.1M3.88M2.36M
Interest Expense00000
Other Income / Expenses190K1.09M3.1M3.88M2.36M
Income Before Tax(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Pre-Tax Margin-2165.6%-3205.5%-60269.1%—-37652.2%
Income Tax Expense00000
Net Income(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Net Margin-2165.6%-3205.5%-60269.1%—-37652.2%
EPS (Basic)(1.20)(1.37)(1.83)(1.27)(1.09)
EPS (Diluted)(1.20)(1.37)(1.83)(1.27)(1.09)
Weighted Avg Shares20.57M24.14M26.6M30.07M31.2M
Weighted Avg Shares (Diluted)20.57M24.14M26.6M30.07M31.2M

Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Intrinsic Alpha fair value

Locked

Current Price

$1.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.